Suppr超能文献

极光激酶B抑制剂AZD1152治疗顺铂耐药卵巢癌的疗效

[Effect of aurora kinase B inhibitor AZD1152 in the treatment of cisplatin-resistant ovarian carcinoma].

作者信息

Ma Ya-xi, Li Xiu-zhen

机构信息

Department of Gynecology, Zhejiang University, Hangzhou, China.

出版信息

Zhonghua Fu Chan Ke Za Zhi. 2013 Jan;48(1):46-50.

Abstract

OBJECTIVE

To investigate whether AZD1152 (AZD), the selective inhibitor of aurora kinase B, may play a role in the treatment of cisplatin-resistant ovarian carcinoma when administrated alone or in combination with cisplatin.

METHODS

Hey (cisplatin-resistant ovarian cancer cell line) cells were analyzed. According to the treatment plan, Hey cells were divided into four groups (AZD group, cisplatin group, AZD + cisplatin group and control group). Methyl thiazolyl tetrazolium (MTT) assay was used to test the cells proliferation, caspase-3/7 activity analysis was used to analyze cells apoptosis, and fluorescence in-situ hybridization (FISH) assay was used to determine the copy the number of chromosome 7 and checked the copy numbers of hTERC gene and C-myc gene.

RESULTS

MTT test showed that proliferation of AZD group was lower than that in control group (P < 0.01). The cells proliferation with the treatment with 10 and 20 nmol/L AZD for 24 hours was (81.4 ± 3.6)% and (81.4 ± 3.6)% respectively, and the cells proliferation for 48 hours was (43.1 ± 2.0)% and (38.5 ± 1.6)% respectively, which was significantly lower than control group (100%, P < 0.01); Treated with the same concentration of AZD, inhibition of proliferation was significantly enhanced as the time extended (P < 0.01). Proliferation in group AZD + cisplatin was lower than that in cisplatin group (P < 0.01) which suggest that there were additive effects after combined AZD with cisplatin. Compared with control group, caspase-3/7 activity in AZD group increased significantly (P = 0.000), and the same results was seen between AZD + cisplatin group and cisplatin group or AZD group (all P < 0.01). Compared with cisplatin group or control group, the copy numbers of hTERC, C-myc and the number of chromosome were significantly increased in AZD group and AZD + cisplat group (all P < 0.05).

CONCLUSIONS

AZD could inhibit ovarian cancer cells proliferation and induce cells apoptosis significantly. AZD alone or in combination with cisplatin may result in the increased cells polyploidy.

摘要

目的

研究极光激酶B的选择性抑制剂AZD1152(AZD)单独使用或与顺铂联合使用时,在顺铂耐药性卵巢癌治疗中是否发挥作用。

方法

对Hey(顺铂耐药性卵巢癌细胞系)细胞进行分析。根据治疗方案,将Hey细胞分为四组(AZD组、顺铂组、AZD +顺铂组和对照组)。采用甲基噻唑基四氮唑蓝(MTT)法检测细胞增殖情况,采用caspase-3/7活性分析法分析细胞凋亡情况,采用荧光原位杂交(FISH)法检测7号染色体的拷贝数,并检测hTERC基因和C-myc基因的拷贝数。

结果

MTT试验显示,AZD组细胞增殖低于对照组(P < 0.01)。用10和20 nmol/L AZD处理24小时后细胞增殖率分别为(81.4 ± 3.6)%和(81.4 ± 3.6)%,处理48小时后分别为(43.1 ± 2.0)%和(38.5 ± 1.6)%,均显著低于对照组(100%,P < 0.01);用相同浓度的AZD处理,随着时间延长,增殖抑制作用显著增强(P < 0.01)。AZD +顺铂组细胞增殖低于顺铂组(P < 0.01),提示AZD与顺铂联合后有相加作用。与对照组相比,AZD组caspase-3/7活性显著增加(P = 0.000),AZD +顺铂组与顺铂组或AZD组之间也有相同结果(均P < 0.01)。与顺铂组或对照组相比,AZD组和AZD +顺铂组hTERC、C-myc的拷贝数及染色体数目均显著增加(均P < 0.05)。

结论

AZD可显著抑制卵巢癌细胞增殖并诱导细胞凋亡。AZD单独使用或与顺铂联合使用可能导致细胞多倍体增加。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验